Rayner
Jim Nevelos has a diverse and extensive work experience in the medical device industry, specifically in joint replacement research and development.
Jim currently serves as the SD, Head of Global Clinical at Rayner, a position they have held since January 2023.
Prior to joining Rayner, Jim worked at Stryker, where they held several leadership roles. From July 2022 to December 2022, they served as the Senior Research Director, Joint Replacement, responsible for aligning research roadmaps and budgets with the business units' strategic directions. Jim also played a crucial role in supporting business development and sales as a subject matter expert. From July 2021 to June 2022, Jim served as the Vice President, Advanced Technology and Research, Joint Replacement, and from April 2021 to July 2021, they held the position of Senior Director, Transatlantic Research, Joint Replacement. Earlier in their tenure at Stryker, they served as the Senior Director of Implant and Robotic Research from January 2015 to March 2021 and as the Director of Hip Research from October 2008 to January 2015. As the Director of Hip Research, Jim managed both in vitro and clinical research and provided strategic direction to the Hip Business Unit. In their role as the Senior Director of Implant and Robotic Research, they managed all Hip, Knee, and Robotic-assisted joint replacement research, including pre-clinical research, investigator-initiated studies, health care economic data, and knowledge management.
Before their time at Stryker, Jim worked as the Hip Marketing Manager at Zimmer UK from February 2005 to June 2006 and as the Product Manager - Hips and Shoulders at Corin from June 2000 to November 2004.
Jim Nevelos has an extensive education history. Jim obtained a Bachelor of Engineering (BEng) in Materials in Engineering from Newcastle University, where they studied from 1992 to 1995. Prior to that, they attended Bradford Grammar from 1981 to 1992. After completing their undergraduate degree, Nevelos pursued a Master of Science (MSc) in Tribology in Machine Design at the University of Leeds from 1995 to 1996. Following this, they continued their studies at the University of Leeds and earned a PhD in Tribology of ceramic-ceramic hips from 1996 to 2000. In addition to their academic achievements, Nevelos obtained a Professional Certificate in Management from The Open University in September 2005.
This person is not in any teams
This person is not in any offices
Rayner
5 followers
Rayner designs and manufactures intraocular lenses and proprietary injection devices for use in cataract surgery. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.With more than 65 years of continuous growth and experience, we remain at the forefront of innovation. Weare focused on providing the best IOLs for clinicians and patients and are driven by science to improve patient outcomes and safety.Primary IOLs Our FDA-approved C-flex aspheric (aberration-neutral) monofocal IOL, as well as our toric and multifocal IOL families are now complemented by the RayOne fully preloaded monofocal IOL injection system. Supplementary IOLsDesigned to be implanted in the ciliary sulcus, Rayner Sulcoflex Pseudophakic Supplementary IOLs are available as aspheric, toric, multifocal and multifocal lenses, and offer a reversible solution for correcting residual post-operative refractive errors following the implantation of a conventional IOL in the capsular bag.OVDsOur Ophteis range offers a full spectrum of OVDs from dispersive to cohesive, enabling surgeons to select the OVD best suited to each specific cataract procedure. Ophteis FR Pro with sorbitol -- designed to deliver a new level of corneal endothelial protection from phaco induced trauma -- is the flagship product of Rayner’s ‘Ophteis’ OVD suite. PharmaceuticalsAlthough the intraocular lens plays a leading role in the visual outcomes of cataract and refractive surgery, the pharmaceuticals that manage the tear film and inflammation are critical to the end result. For that reason, Rayner recently acquired the business of Moorfields Pharmaceuticals. The acquisition will enable us to offer an even wider range of ophthalmic tools that aid and streamline the surgical process whilst remaining focused on the visual outcome for the patient.Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 80 countries with direct markets in UK, Germany & Austria, the United States of America, Italy and Spain. We have the world’s longest commercial history of IOL design and manufacturing and have worked with cataract surgeons for longer than anyone else.In 2016, Rayner transferred its global headquarters to a brand new state of the art manufacturing plant, which has dramatically increased the company’s production capacity.